RU2565542C2 - Улучшенная композиция для ингибирования пролиферации опухолевых клеток - Google Patents

Улучшенная композиция для ингибирования пролиферации опухолевых клеток Download PDF

Info

Publication number
RU2565542C2
RU2565542C2 RU2012137173/10A RU2012137173A RU2565542C2 RU 2565542 C2 RU2565542 C2 RU 2565542C2 RU 2012137173/10 A RU2012137173/10 A RU 2012137173/10A RU 2012137173 A RU2012137173 A RU 2012137173A RU 2565542 C2 RU2565542 C2 RU 2565542C2
Authority
RU
Russia
Prior art keywords
cancer
tumor
pro
cells
inflammatory
Prior art date
Application number
RU2012137173/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012137173A (ru
Inventor
Алекс КАРЛССОН-ПАРРА
Бенгт АНДЕРССОН
Анна Карин ВАЛЛГРЕН
Original Assignee
Иммуникум Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммуникум Аб filed Critical Иммуникум Аб
Publication of RU2012137173A publication Critical patent/RU2012137173A/ru
Application granted granted Critical
Publication of RU2565542C2 publication Critical patent/RU2565542C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012137173/10A 2010-02-10 2011-02-10 Улучшенная композиция для ингибирования пролиферации опухолевых клеток RU2565542C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
SE1050133 2010-02-10
SE1050133-6 2010-02-10
US61/303,153 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (2)

Publication Number Publication Date
RU2012137173A RU2012137173A (ru) 2014-03-20
RU2565542C2 true RU2565542C2 (ru) 2015-10-20

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012137173/10A RU2565542C2 (ru) 2010-02-10 2011-02-10 Улучшенная композиция для ингибирования пролиферации опухолевых клеток

Country Status (13)

Country Link
US (1) US9034317B2 (enExample)
EP (1) EP2534242B1 (enExample)
JP (1) JP5855018B2 (enExample)
KR (1) KR101770785B1 (enExample)
CN (1) CN102782123B (enExample)
BR (1) BR112012019267B1 (enExample)
DK (1) DK2534242T3 (enExample)
ES (1) ES2581277T3 (enExample)
HU (1) HUE028352T2 (enExample)
PL (1) PL2534242T3 (enExample)
RU (1) RU2565542C2 (enExample)
SI (1) SI2534242T1 (enExample)
WO (1) WO2011098516A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591230T3 (es) 2012-12-18 2016-11-25 Immunicum Ab Co-diferenciación y activación de monocitos procedentes de donantes alogénicos para producir células dendríticas pro-inflamatorias
AU2016259020B2 (en) * 2015-05-07 2021-12-09 Baylor College Of Medicine Dendritic cell immunotherapy
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
CA3037882A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
SI3460052T1 (sl) * 2017-09-20 2020-03-31 Immunicum Ab Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2348418C2 (ru) * 2002-12-06 2009-03-10 Норсуэст Байотерапьютикс, Инк. Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101883845B (zh) 2007-10-08 2015-06-10 英特瑞克斯顿股份有限公司 工程树突细胞及其在癌症治疗中的应用
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2348418C2 (ru) * 2002-12-06 2009-03-10 Норсуэст Байотерапьютикс, Инк. Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUJITA M. et al., Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10, Cancer Res., 2009, v.69, n.4, p.1587-1595. GAUTIER G. et al., A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells, J. Exp. Med., 2005, v.201,n.9, p.1435-1446. GRAUER O. et al., Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2, J. Neurooncol., 2007, v.82,n.2,p.151-161. LEBRE M.C. et al., Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: A role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation, Immunology and Cell Biology, 2005, v.83, p.525"535. AHONEN C.L. et al., Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the nove *

Also Published As

Publication number Publication date
DK2534242T3 (en) 2016-07-18
EP2534242A1 (en) 2012-12-19
WO2011098516A1 (en) 2011-08-18
PL2534242T3 (pl) 2016-11-30
US20120328662A1 (en) 2012-12-27
BR112012019267A2 (pt) 2020-10-06
HUE028352T2 (en) 2016-12-28
JP5855018B2 (ja) 2016-02-09
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
CN102782123B (zh) 2016-05-11
KR20120114358A (ko) 2012-10-16
BR112012019267B1 (pt) 2022-03-03
KR101770785B1 (ko) 2017-08-23
ES2581277T3 (es) 2016-09-05
JP2013519363A (ja) 2013-05-30
US9034317B2 (en) 2015-05-19
EP2534242B1 (en) 2016-04-20
RU2012137173A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
RU2565542C2 (ru) Улучшенная композиция для ингибирования пролиферации опухолевых клеток
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
CN102597222B (zh) 用于增殖抗原特异性t细胞的方法
US20160040128A1 (en) Method
Petersen et al. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines
IL292009A (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
IL286225B2 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
Zapala et al. Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application
JP7146732B2 (ja) 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
WO2025221993A1 (en) Compositions and methods for producing il-16
US20120076827A1 (en) Compositions and methods for generating an immune response in a subject
Ali Programming cells in situ

Legal Events

Date Code Title Description
HC9A Changing information about inventors